arrow
Y

Yubin Kang

Duke Medical Center
H指数:33
被引数:4,468

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Single-centre analysis of prophylactic dexamethasone on the incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity in patients receiving axicabtagene ciloleucel

预防性地塞米松对接受axicabtagene ciloleucel的患者细胞因子释放综合征和免疫效应细胞相关神经毒性的发生率和严重程度的单中心分析

2026-01-190
PRE
Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation

优化型单硫醇硫氧还蛋白衍生物(ORP100S)在体外和体内均能保护组织免受辐射和化学毒性的损伤,且不促进肿瘤增殖。

2025-09-110
OAAI
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025

NCCN Guidelines® Insights: 多发性骨髓瘤,版本 1.2025

2025-05-010
PRE
Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort

理解血液恶性肿瘤患者造血干细胞移植中的社会经济障碍:来自北卡罗来纳队列的见解

BLOOD
IF23.1
2024-11-050
PRE
Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

CAR-T疗法可及性与结局的不平等:在北卡罗来纳州某学术中心新诊断恶性肿瘤患者中CAR-T疗法转诊模式的差异

BLOOD
IF23.1
2024-11-050
PRE
Longitudinal intravital imaging of mouse placenta
2024-03-228
OAAI
Chromatin Remodeling in Patient-Derived Colorectal Cancer Models

患者来源的结直肠癌模型中的染色质重塑

2024-02-210
OAAI
Waldenstro m Macroglobulinemia/ Lymphoplasmacytic Lymphoma, Version 2.2024
2024-01-011
OA
Multiple Myeloma, Version 2.2024
2023-12-0123
OA
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease

Fostamatinib抑制SYK在预防和治疗慢性移植物抗宿主病中的I期试验

2023-03-0110
OAAI